Dana Farber Cancer Institute.

Clinical research site in Boston, Massachusetts · 450 BROOKLINE AVE, BOSTON, MA 02215-5418 · (617) 632-3000 · Website

Part of Dana-Farber Cancer Institute

As of July 2026, 598 paid clinical trials are recruiting at Dana Farber Cancer Institute. in Boston, Massachusetts. Active studies at this site cover conditions such as Breast Cancer, Acute Myeloid Leukemia and Multiple Myeloma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Dana Farber Cancer Institute. (598)

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

for Adenovirus Infections

26 locations incl. Phoenix

Sponsor: SymBio Pharmaceuticals

Sex: All·Age: 2 Months+

Code: NCT07387367·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

for Breast Neoplasms

28 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: Female·Age: 18+

Code: NCT07287098·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

for Carcinoma, Renal Cell

109 locations incl. Phoenix

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227415·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for Intestinal Neoplasms

166 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222800·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

for Squamous Cell Carcinoma of Head and Neck

45 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07276399·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

for Pancreatic Cancer

29 locations incl. Los Angeles

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07252232·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

116 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

for Non-small Cell Lung Cancer

28 locations incl. Fresno

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT07195695·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostate Neoplasms

53 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

169 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

124 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

50 locations incl. Casa Grande

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

104 locations incl. Anchorage

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting·Listed May 2020

Apply to this trial

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

for Early Breast Cancer

85 locations incl. Birmingham

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT05827081·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for Lymphoma, Large B-Cell, Diffuse

71 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

52 locations incl. Gilbert

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

for Advanced Non-Small Cell Lung Cancer

192 locations incl. Goodyear

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT04613596·Phase 2, Phase 3·Recruiting·Listed Nov 2020

Apply to this trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

54 locations incl. Daphne

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06065748·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

for Chronic Lymphocytic Leukemia

37 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06973187·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

77 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

for Non-Small Cell Lung Cancer

26 locations incl. Irvine

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07100080·Phase 2, Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

36 locations incl. Birmingham

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06158841·Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

for Chronic Lymphocytic Leukemia

35 locations incl. Laguna Hills

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06943872·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

26 locations incl. Cerritos

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

for Advanced Solid Tumor

24 locations incl. Tucson

Sponsor: Synthekine

Sex: All·Age: 18+

Code: NCT05098132·Phase 1, Phase 2·Recruiting·Listed Oct 2021

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

for Leukemia, Myeloid, Acute

51 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06852222·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

for Small Cell Lung Cancer

27 locations incl. Daphne

Sponsor: Puma Biotechnology, Inc.

Sex: All·Age: 18+

Code: NCT06095505·Phase 2·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

for Metastatic Non-small Cell Lung Cancer With MTAP Deletion

39 locations incl. Anchorage

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07063745·Phase 2, Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

for Multiple Myeloma

28 locations incl. Phoenix

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05201781·Phase 4·Recruiting·Listed Jan 2022

Apply to this trial

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

for Pancreatic Neuroendocrine Tumor (pNET)

40 locations incl. Birmingham

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT06943755·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

for Breast Neoplasms

38 locations incl. Hot Springs

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06926868·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

for Melanoma

58 locations incl. Birmingham

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05538130·Phase 1·Recruiting·Listed Sep 2022

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for Prostate Cancer

49 locations incl. Phoenix

Sponsor: Merck Sharp & Dohme LLC

Sex: Male·Age: 18+

Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

for Glioma

42 locations incl. Birmingham

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

A Study of ASP3082 in Adults With Advanced Solid Tumors

for Solid Tumor

24 locations incl. Duarte

Sponsor: Astellas Pharma Inc

Sex: All·Age: 18+

Code: NCT05382559·Phase 1·Recruiting·Listed May 2022

Apply to this trial

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

for Pancreatic Ductal Adenocarcinoma

25 locations incl. Duarte

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06586515·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

for Oligometastatic Prostate Cancer (OMPC)

40 locations incl. Fayetteville

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18 - 100

Code: NCT05939414·Phase 3·Recruiting·Listed Jul 2023

Apply to this trial

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

for Non-Small Cell Lung Cancer, NSCLC

28 locations incl. Gilbert

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06162221·Phase 1, Phase 2·Recruiting·Listed Dec 2023

Apply to this trial

Showing the 40 most relevant of 598 recruiting trials at this site. Browse all with filters →

More research sites in Boston

Massachusetts General Hospital (694 trials)
Brigham and Women's Hospital (346 trials)
Dana-Farber Cancer Institute (341 trials)
Beth Israel Deaconess Medical Center (265 trials)
Boston Children's Hospital (259 trials)
Dana Farber Cancer Institute (221 trials)
Tufts Medical Center (107 trials)
Boston Medical Center (94 trials)
Massachusetts General Hospital Cancer Center (57 trials)
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA (28 trials)

Explore more

Paid clinical trials in Boston, MA · Massachusetts clinical trials